nach oben

Current Osteoporosis Reports

Erschienen in:

21.04.2017 | Therapeutics and Medical Management (S Jan de Beur and B Clarke, Section editors)

Exploiting the WNT Signaling Pathway for Clinical Purposes

verfasst von: Mark L. Johnson, Robert R. Recker

Erschienen in: Current Osteoporosis Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001–2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting. It has provided many opportunities for exploitation to develop new clinical treatments, particularly for osteoporosis. More clinical possibilities include: treatments for fracture healing, corticosteroid osteoporosis, osteogenesis imperfecta, and others. In addition, we wish to provide historical information coming from distant publications (~350 years ago) regarding bone biology that have been confirmed by study of Wnt signaling.

Recent Findings

A recent finding is the development of an antibody to sclerostin that is under study as a treatment for osteoporosis.

Summary

Development of treatments for other forms of osteoporosis, such as corticosteroid osteoporosis, is also underway. The full range of the applications of the work is not yet been achieved.

Frost HM. A 2003 update of bone physiology and Wolff's Law for clinicians. Angle Orthod. 2004;74:3–15.PubMed

Galilei G. Two New Sciences. 1914.

Frost HM. Bone’s mechanostat: a 2003 update. Anat Rec. 2003;275:1081–101.CrossRef

Lanyon LE. Functional strain in bone tissue as an objective, and controlling stimulus for adaptive bone remodeling. J Biomech. 1987;20:1083–93.PubMedCrossRef

Lanyon LE. Osteocytes, strain detection, bone modeling and remodeling. CalcifTissue Int. 1993;53(Suppl 1):S102–6.

Lanyon L, Skerry T. Postmenopausal osteoporosis as a failure of bone’s adaptation to functional loading: a hypothesis. J Bone Miner Res. 2001;16(11):1937–47.PubMedCrossRef

• Frost HM, Ferretti JL, Jee WSS. Some roles of mechanical usage, muscle strength, and the mechanostat in skeletal physiology, disease, and research. Calcif Tissue Int. 1998;62:1–7. This reference is important because it characterizes the historical background that led to the discovery of the G171V mutation in the kindred of reference 10. PubMedCrossRef

Wolf J. Concept of the Law of Bone Remodeling. In The Law of bone remodeling. 1986.

Frost HM. Changing concepts in skeletal physiology: Wolff’s law, the mechanostat, and the “Utah Paradigm”. Am J Hum Biol. 1998;10:599–605.CrossRef

10.

• Little RD, Carulli JP, del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao S-C, Eustace B, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70:11–9. This reference is important because it describes the work that resulted in the discovery of the G171V mutation in a High Bone Mass kindred, and resulted in the pursuit of anabolic pharmacologic treatments for osteoporosis and other bone anomalies. PubMedCrossRef

11.

Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.PubMedCrossRef

12.

Johnson ML, Harnish K, Nusse R, van Hul W. Review—Lrp5 and Wnt signaling: a union made for bone. J Bone Miner Res. 2004;19:1749–57.PubMedCrossRef

13.

Niziolek PJ, Farmer TL, Cui Y, Turner CH, Warman ML, Robling AG. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes. Bone. 2011;49(5):1010–9.PubMedPubMedCentralCrossRef

14.

Gong Y, Vikkula M, Boon L, Liu J, Beighton P, Ramesar R, Peltonen L, Somer H, Hirose T, Dallapiccola B, et al. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet. 1996;59:146–51.PubMedPubMedCentral

15.

Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature. 2000;407(6803):535–8.PubMedCrossRef

16.

Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A, DiNardo S. arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature. 2000;407(6803):527–30.PubMedCrossRef

17.

Byers S, Shah S. Vitamin D and the regulation of Wnt/b-catenin signaling and innate immunity in colorectal cancer. Nutr Rev. 2007;65:S118–20.PubMedCrossRef

18.

Thiele S, Rachner TD, Rauner M, Hofbauer LC. WNT5A and its receptors in the bone-cancer dialogue. J Bone Miner Res. 2016;31(8):1488–96.PubMedCrossRef

19.

Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. DevDyn. 2010;239(1):102–14.

20.

Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J HumGenet. 2001;68(3):577–89.PubMedPubMedCentralCrossRef

21.

Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). HumMolGenet. 2001;10(5):537–43.

22.

Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–7.PubMedPubMedCentralCrossRef

23.

Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110(2):144–52.PubMedCrossRef

24.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol.Chem. 2005;280(20):19883–7.PubMedCrossRef

25.

Ellies DL, Viviano B, McCarthy J, Rey J-P, Itasaki N, Saunders S, Krumlauf R. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5^G171V to modulate Wnt activity. J Bone Miner Res. 2006;21:1738–49.PubMedCrossRef

26.

Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol.Endocrinol. 2004;18(5):1222–37.PubMedCrossRef

27.

Ellies DL, Economou A, Viviano B, Rey JP, Paine-Saunders S, Krumlauf R, Saunders S. Wise regulates bone deposition through genetic interactions with Lrp5. PLoSOne. 2014;9(5):e96257.CrossRef

28.

Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606–15.PubMedPubMedCentralCrossRef

29.

Johnson ML. LRP5 and bone mass regulation: where are we now? BoneKEy Rep. 2012;1:1.PubMedPubMedCentralCrossRef

30.

Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. NatMed. 2013;19(2):179–92.

31.

Burgers TA, Williams BO. Regulation of Wnt/beta-catenin signaling within and from osteocytes. Bone. 2013;54(2):244–9.PubMedPubMedCentralCrossRef

32.

Lara-Castillo N, Johnson ML. LRP receptor family member associated bone disease. Rev EndocrMetab Disord. 2015;16(2):141–8.CrossRef

33.

Kobayashi Y, Uehara S, Udagawa N, Takahashi N. Regulation of bone metabolism by Wnt signals. J Biochem. 2016;159(4):387–92.PubMedCrossRef

34.

Duan P, Bonewald LF. The role of the wnt/beta-catenin signaling pathway in formation and maintenance of bone and teeth. IntJ BiochemCell Biol. 2016;77(Pt A):23–9.CrossRef

35.

Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 1996;86(3):391–9.PubMedCrossRef

36.

Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science. 2005;308(5725):1181–4.PubMedCrossRef

37.

Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol.Chem. 2007;282(37):27298–305.PubMedCrossRef

38.

Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki GR, Babij P, Allen KM, Yaworsky PJ, Bex F, et al. Bone biomechanical properties in LRP5 mutant mice. Bone. 2004;35:162–9.PubMedCrossRef

39.

Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, Cullen DM, Zhao W, Li C, Kharode Y, Sauter L, Babij P, Brown EL, et al. WNT/b-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006;281:31720–8.PubMedCrossRef

40.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2007;28:23698–711.

41.

Niziolek PJ, Warman ML, Robling AG. Mechanotransduction in bone tissue: the A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner. Bone. 2012;51(3):459–65.PubMedPubMedCentralCrossRef

42.

Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. MolCell Biol. 2010;30(12):3071–85.

43.

Javaheri B, Stern AR, Lara N, Dallas M, Zhao H, Liu Y, Bonewald LF, Johnson ML. Deletion of a single beta-catenin allele in osteocytes abolishes the bone anabolic response to loading. J Bone Miner Res. 2014;29(3):705–15.PubMedPubMedCentralCrossRef

44.

Kang KS, Hong JM, Robling AG. Postnatal beta-catenin deletion from Dmp1-expressing osteocytes/osteoblasts reduces structural adaptation to loading, but not periosteal load-induced bone formation. Bone. 2016;88:138–45.PubMedCrossRef

45.

Holguin N, Brodt MD, Silva MJ. Activation of Wnt signaling by mechanical loading is impaired in the bone of old mice. J Bone Miner Res. 2016;31(12):2215–26.PubMedPubMedCentralCrossRef

46.

Farr JN, Roforth MM, Fujita K, Nicks KM, Cunningham JM, Atkinson EJ, Therneau TM, McCready LK, Peterson JM, Drake MT, et al. Effects of age and estrogen on skeletal gene expression in humans as assessed by RNA sequencing. PLoS.One. 2015;10(9):e0138347.PubMedPubMedCentralCrossRef

47.

Jiang JX, Cherian PP. Hemichannels formed by connexin 43 play an important role in the release of prostaglandin E(2) by osteocytes in response to mechanical strain. Cell CommunAdhes. 2003;10(4–6):259–64.

48.

Cherian PP, Cheng B, Gu S, Sprague E, Bonewald LF, Jiang JX. Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J Biol.Chem. 2003;278(44):43146–56.PubMedCrossRef

49.

Akhter MP, Cullen DM, Pan LC. Bone biomechanical properties in EP4 knockout mice. Calcif Tissue Int. 2006;78:357–62.PubMedCrossRef

50.

Galea GL, Sunters A, Meakin LB, Zaman G, Sugiyama T, Lanyon LE, Price JS. Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett. 2011;585(15):2450–4.PubMedPubMedCentralCrossRef

51.

Tian Q, He XC, Hood L, Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle. 2005;4(2):215–6.PubMedCrossRef

52.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005;310(5753):1504–10.PubMedCrossRef

53.

Sunters A, Armstrong VJ, Zaman G, Kypta RM, Kawano Y, Lanyon LE, Price JS. Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor alpha-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling. J Biol.Chem. 2010;285(12):8743–58.PubMedCrossRef

54.

Armstrong V, Muzylak M, Sunters A, Zaman G, Saxon LK, Price JS, Lanyon LE. Wnt/β-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor-alpha. J Biol Chem. 2007;282:20715–27.PubMedCrossRef

55.

Lara-Castillo N, Kim-Weroha NA, Kamel MA, Javaheri B, Ellies DL, Krumlauf RE, Thiagarajan G, Johnson ML. In vivo mechanical loading rapidly activates β-catenin signaling in osteocytes through a prostaglandin mediated mechanism. Bone. 2015;76:58–66.PubMedPubMedCentralCrossRef

56.

Hens JR, Wilson KM, Dann P, Chen X, Horowitz MC, Wysolmerski J. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res. 2005;20:1103–13.PubMedCrossRef

57.

Wu M, Chen G, Li YP. TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009.PubMedPubMedCentralCrossRef

58.

Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development. 2008;135(22):3801–11.PubMedPubMedCentralCrossRef

59.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267–76.PubMedPubMedCentralCrossRef

60.

Van Bezooijen RL, Roelen BA, Visser A, Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, Ten Dijke P, Lowik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J ExpMed. 2004;199(6):805–14.CrossRef

61.

Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J BiolChem. 2008;283(9):5866–75.

62.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50(1):209–17.PubMedCrossRef

63.

Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, Lanyon LE, Price JS. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos.Int. 2012;23(4):1225–34.PubMedCrossRef

64.

Nguyen J, Tang SY, Nguyen D, Alliston T. Load regulates bone formation and Sclerostin expression through a TGFbeta-dependent mechanism. PLoSOne. 2013;8(1):e53813.CrossRef

65.

Weivoda MM, Oursler MJ. Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions. CurrOsteoporosRep. 2014;12(1):107–14.

66.

Galea GL, Price JS, Lanyon LE. Estrogen receptors’ roles in the control of mechanically adaptive bone (re)modeling. BoneKEy Rep. 2013;2:413.PubMedPubMedCentralCrossRef

67.

Wein MN, Spatz J, Nishimori S, Doench J, Root D, Babij P, Nagano K, Baron R, Brooks D, Bouxsein M, et al. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Miner Res. 2015;30(3):400–11.PubMedPubMedCentralCrossRef

68.

Obri A, Makinistoglu MP, Zhang H, Karsenty G. HDAC4 integrates PTH and sympathetic signaling in osteoblasts. J Cell Biol. 2014;205(6):771–80.PubMedPubMedCentralCrossRef

69.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res. 2012;27(2):360–73.PubMedCrossRef

70.

Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010;46(6):1486–97.PubMedCrossRef

71.

Kamiya N, Shuxian L, Yamaguchi R, Phipps M, Aruwajoye O, Adapala NS, Yuan H, Kim HK, Feng JQ. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength. Bone. 2016;91:53–63.PubMedCrossRef

72.

Delgado-Calle J, Arozamena J, Perez-Lopez J, Bolado-Carrancio A, Sanudo C, Agudo G, de la Vega R, Alonso MA, Rodriguez-Rey JC, Riancho JA. Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells. MolCell Endocrinol. 2013;369(1–2):27–34.

73.

Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type 1A receptor (BMPRIA) in osteoblasts. J Bone Miner Res. 2010;25:200–10.PubMedCrossRef

74.

Wijenayaka AR, Yang D, Prideaux M, Ito N, Kogawa M, Anderson PH, Morris HA, Solomon LB, Loots GG, Findlay DM, et al. 1alpha,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. MolCell Endocrinol. 2015;413:157–67.

75.

Wijenayaka AR, Prideaux M, Yang D, Morris HA, Findlay DM, Anderson PH, Atkins GJ. Early response of the human SOST gene to stimulation by 1alpha,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2015.

76.

Fretz JA, Zella LA, Kim S, Shevde NK, Pike JW. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription. MolEndocrinol. 2006;20(9):2215–30.

77.

Johnson ML, Gong G, Kimberling W, Recker SM, Kimmel DB, Recker RR. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet. 1997;60:1326–32.PubMedPubMedCentralCrossRef

78.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–23.PubMedCrossRef

79.

Portal-Nunez S, Lozano D, de Castro LF, de Gortazar AR, Nogues X, Esbrit P. Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett. 2010;584(14):3095–100.PubMedCrossRef

80.

Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. ExpertOpinTher Targets. 2009;13(4):485–96.

81.

Benson C, Robins D, Recker R, Alam J, Chiang AY, Mitlak B, Sipos A, Hu L. Effect of blosozumab on bone mineral density_results of a phase 2 study of postmenopausal women with low bone mineral density. Bioscientifica. 2013. Ref Type: Abstract

82.

McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935–43.PubMedCrossRef

83.

• McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, et al. Romosozumab in postmenopausal women with low bone mineral density. NEnglJMed. 2014;1370:412–20. This reference is important because it descibes a new treatment (a sclerostin antibody, Romososumab) for osteoporosis demonstrating anabolic results of a Phase II study with as much as 17% increase in bone density in as little as 12 months. CrossRef

84.

Recker R, Benson C, Matsumoto T, Bolognese M, Robins D, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2014;30(2):216–24.CrossRef

85.

Graeff C, Campbell GM, Pena J, Borggrefe J, Padhi D, Kaufman A, Chang S, Libanati C, Gluer CC. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364–9.PubMedCrossRef

86.

Becker CB. Sclerostin inhibition for osteoporosis—a new approach. N.Engl.J.Med. 2014;370(5):476–7.PubMedCrossRef

87.

Recknor CP, Recker RR, Benson CT, Robins DA, Chiang AY, Alam J, Hu L, Matsumoto T, Sowa H, Sloan JH, et al. The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(9):1717–25.PubMedCrossRef

88.

Amgen And UCB Announce positive top-line results from the phase 3 study of romosozumab in postmenopausal women with osteoporosis France Nivelle, Global Communications, UCB: Amgen, Inc; 2016.

89.

Komatsu DE, Mary MN, Schroeder RJ, Robling AG, Turner CH, Warden SJ. Modulation of Wnt signaling influences fracture repair. J Orthop Res. 2010;28:928–36.PubMedPubMedCentral

90.

Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, Alman BA. Beta-catenin signaling plays a disparate role in different phases of fracture repair: implications for therapy to improve bone healing. PLoSMed. 2007;4(7):e249.

91.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han C-Y, Vlasseros F, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26:1012–21.PubMedCrossRef

92.

Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25:2412–8.PubMedCrossRef

93.

Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res. 2011;26(11):2610–21.PubMedCrossRef

94.

Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2):371–9.PubMedPubMedCentralCrossRef

95.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy Jr JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24(3):425–36.PubMedCrossRef

96.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy Jr JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2004;349:2483–94.CrossRef

97.

Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. AnnRheumDis. 2010;69(3):592–7.

98.

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60(11):3257–62.PubMedCrossRef

99.

Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73–80.PubMedPubMedCentralCrossRef

100.

Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95(4):1991–7.PubMedPubMedCentralCrossRef

101.

Modder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone. 2011;49:202–7.PubMedPubMedCentralCrossRef

102.

Modder UIL, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27–34.PubMedCrossRef

103.

Chung YE, Lee SH, Lee SY, Kim SY, Kim HH, Mirza FS, Lee SK, Lorenzo JA, Kim GS, Koh JM. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. OsteoporosInt. 2012;23(4):1235–43.CrossRef

104.

Rossini M, Gatti D, Adami S. Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis. CalcifTissue Int. 2013;93(2):121–32.

105.

Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II. Serum extracellular secreted antagonists of the canonical Wnt/beta-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporos Int. 2013;24(8):2191–9.PubMedCrossRef

106.

Gifre L, Ruiz-Gaspa S, Monegal A, Nomdedeu B, Filella X, Guanabens N, Peris P. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone. 2013;57(1):272–6.PubMedCrossRef

107.

Fahiminiya S, Majewski J, Mort J, Moffatt P, Glorieux FH, Rauch F. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet. 2013;50(5):345–8.PubMedCrossRef

108.

Laine CM, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, Lu JT, Pekkinen M, Wessman M, Heino TJ, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013;368(19):1809–16.PubMedPubMedCentralCrossRef

109.

Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56(1):42–7.PubMedCrossRef

110.

Lim WH, Liu B, Cheng D, Hunter DJ, Zhong Z, Ramos DM, Williams BO, Sharpe PT, Bardet C, Mah SJ, et al. Wnt signaling regulates pulp volume and dentin thickness. J Bone Miner Res. 2014;29(4):892–901.PubMedPubMedCentralCrossRef

111.

Hunter DJ, Bardet C, Mouraret S, Liu B, Singh G, Sadoine J, Dhamdhere G, Smith A, Tran XV, Joy A, et al. Wnt acts as a prosurvival signal to enhance dentin regeneration. J Bone Miner Res. 2015;30(7):1150–9.PubMedCrossRef

112.

Han P, Ivanovski S, Crawford R, Xiao Y. Activation of the canonical Wnt signaling pathway induces cementum regeneration. J Bone Miner Res. 2015;30(7):1160–74.PubMedCrossRef

113.

Fu HD, Wang BK, Wan ZQ, Lin H, Chang ML, Han GL. Wnt5a mediated canonical Wnt signaling pathway activation in orthodontic tooth movement: possible role in the tension force-induced bone formation. J MolHistol. 2016;47(5):455–66.CrossRef

114.

Lu J, Duan Y, Zhang M, Wu M, Wang Y. Expression of Wnt3a, Wnt10b, beta-catenin and DKK1 in periodontium during orthodontic tooth movement in rats. Acta OdontolScand. 2016;74(3):217–23.CrossRef

Titel: Exploiting the WNT Signaling Pathway for Clinical Purposes
verfasst von: Mark L. Johnson
Robert R. Recker
Publikationsdatum: 21.04.2017
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 3/2017
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-017-0357-0

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Exploiting the WNT Signaling Pathway for Clinical Purposes

Abstract

Purpose of Review

Recent Findings

Summary

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

TEP mit Roboterhilfe führt nicht zu größerer Zufriedenheit

Lever-Sign-Test hilft beim Verdacht auf Kreuzbandriss

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Orthopädie und Unfallchirurgie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder

What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease

Parathyroid Diseases and T Cells

T Regulatory Cells in Bone Remodelling

The Role of the Molecular Clock in Skeletal Muscle and What It Is Teaching Us About Muscle-Bone Crosstalk

Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

TEP mit Roboterhilfe führt nicht zu größerer Zufriedenheit

Lever-Sign-Test hilft beim Verdacht auf Kreuzbandriss

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Orthopädie und Unfallchirurgie